Publication | Open Access

Increased versus conventional adalimumab dose interval for patients with Crohn's disease in stable remission (LADI): a pragmatic, open-label, non-inferiority, randomised controlled trial

Clinical TrialsGastroenterologyTreatment OptionClinical GastroenterologyUlcerative ColitisMedicineStable Remission